Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma

(2018) Liang Zeng et al.   Journal of Thoracic Oncology

Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex

(2018) Minglei Yang et al.   LUNG CANCER

High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation

(2018) Panwen Tian et al.   LUNG CANCER

EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib

(2017) Uroosa Ibrahim et al.   LUNG CANCER

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations

(2017) Yi-Cheng Shen et al.   LUNG CANCER

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

(2017) Hai-Yan Tu et al.   LUNG CANCER

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy

(2017) Diego Kauffmann-Guerrero et al.   RESPIRATION

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

(2017) Chih-Jen Yang et al.   BMC Pharmacology & Toxicology

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

(2017) Chih-Jen Yang et al.   BMC Pharmacology & Toxicology

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

(2016) Chih-Jen Yang et al.   OncoTargets and Therapy

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor

(2016) Chih-Jen Yang et al.   OncoTargets and Therapy

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

(2015) Y. Kobayashi et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

(2015) Chao-Hua Chiu et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib

(2015) Kuan-Li Wu et al.   LUNG CANCER

Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma

(2014) Jui-Sheng Hsu et al.   JOURNAL OF THORACIC IMAGING

Two Cases of Non–Small-Cell Lung Cancer with Rare Complex Mutation of EGFR Exon 18 But Different Response to Targeted Therapy

(2014) Hélène Gauthier et al.   Journal of Thoracic Oncology

Rare EGFR Exon 20 S768I Mutation Predicts Resistance to Targeted Therapy: A Report of Two Cases

(2014) Lalit Pallan et al.   Journal of Thoracic Oncology

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

(2012) Susumu Kobayashi et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

(2009) R. K. Kancha et al.   CLINICAL CANCER RESEARCH

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck

(2008) Ilona Schwentner et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

(2008) Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY